Cardiotoxicity and pro-inflammatory effects of the immune checkpoint inhibitor Pembrolizumab associated to Trastuzumab
Vincenzo Quagliariello(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Nicola Maurea(Cancer Institute (WIA)), Paolo A. Ascierto(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Margherita Passariello(Federico II University Hospital), Carmela Coppola, Antônio Barbieri, Claudia De Lorenzo(Istituto Nazionale di Fisica Nucleare, Sezione di Napoli), Domenica Rea(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), M. Monti(Federico II University Hospital), Marino Scherillo, Gerardo Botti(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), R. V. Iaffaioli(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Michelino De Laurentiis(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale")
Cited by 64
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
|New England Journal of Medicine|2017|2.2k
Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma
|New England Journal of Medicine|2014|2k
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
|New England Journal of Medicine|2018|1.9k